Millennium Management LLC Buys Shares of 153,207 BioSig Technologies, Inc. (NASDAQ:BSGM)

Millennium Management LLC acquired a new stake in BioSig Technologies, Inc. (NASDAQ:BSGM - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 153,207 shares of the company's stock, valued at approximately $228,000. Millennium Management LLC owned 0.89% of BioSig Technologies as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also bought and sold shares of BSGM. Geode Capital Management LLC acquired a new stake in shares of BioSig Technologies in the 4th quarter worth about $143,000. Legacy Investment Solutions LLC bought a new position in shares of BioSig Technologies in the fourth quarter valued at approximately $5,369,000. Finally, Integrity Wealth Advisors Inc. purchased a new position in shares of BioSig Technologies during the fourth quarter valued at approximately $61,000. Institutional investors and hedge funds own 7.16% of the company's stock.

Analyst Ratings Changes

Separately, Ascendiant Capital Markets increased their price target on BioSig Technologies from $2.50 to $10.00 and gave the company a "buy" rating in a research report on Friday, June 6th.

BioSig Technologies Stock Up 3.1%

Shares of BSGM traded up $0.21 during trading hours on Thursday, reaching $6.91. 970,642 shares of the stock traded hands, compared to its average volume of 318,084. BioSig Technologies, Inc. has a 52 week low of $0.23 and a 52 week high of $8.80. The stock has a fifty day simple moving average of $2.71 and a 200 day simple moving average of $1.65.

BioSig Technologies (NASDAQ:BSGM - Get Free Report) last posted its earnings results on Monday, May 19th. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.09). Research analysts expect that BioSig Technologies, Inc. will post -0.88 earnings per share for the current fiscal year.

BioSig Technologies Profile

BioSig Technologies, Inc, together with its subsidiaries, a medical device company, engages in development and commercialization of advanced digital signal processing technology platform for the treatment of cardiovascular arrhythmias in the United States. It offers PURE EP system, a signal processing platform that combines hardware and software to address known challenges associated to signal acquisition that enables electrophysiologists to see signals and analyze in real-time, as well as is designed to address long-standing limitations that slow and disrupt cardiac catheter ablation procedures.